Kenvue Inc. KVUE Moat

Key data

The moat

Households buy Tylenol, Band-Aid, Listerine and Neutrogena under mild duress, at low ticket, with no time to compare labels, and the thing lost by switching is the certainty that the product worked last time on someone they care about. That is a classic brand moat, deepened by one feature few consumer companies hold: these are drug monograph products in categories where pharmacists and pediatricians name a brand out loud. Confidence is moderate, because the trust is real and measurable in margin while the share data that would prove it is management's own. Swap in Church & Dwight, Estee Lauder or Perrigo and the sentence collapses, since none of them owns a century-old default answer to a fever, a cut or a mouth rinse that a clinician repeats for free.

What the moat produces is price, not volume. In FY2024 the company took 2.7% of favorable value realization, defined as price including mix, against a 1.2% volume decline, and gross margin ran 56.0% to 58.0% to 58.1% across FY2023 to FY2025 while revenue went $15.44 billion, $15.46 billion, $15.12 billion.

The secondary moat is scale in manufacturing and retail coverage, and it is thin. In-house plants delivered over 60% of sales volume in FY2024, and revenue per employee slipped from $702 thousand to $687 thousand. Returns say the same thing: ROIC of 8.9%, 8.3%, 6.2%, 8.8% from FY2022 to FY2025 never cleared 9% in four years.

Widening or narrowing

Three sequences point one way. Skin Health and Beauty revenue fell $4.38 billion to $4.24 billion to $4.11 billion, and the FY2024 filing attributes the US piece to execution carryover plus current-year competitive pressures, which is a competitive loss, not a comparison base. North America, three quarters of the profit base by geography weighting, went $7.61 billion, $7.58 billion, $7.26 billion. And gross margin added 200 basis points into FY2024 then 10 basis points into FY2025, so the pricing engine has stalled near 58%.

The profit pool in consumer health sits with the brand owner, and here the slice is still fat: store-brand manufacturer Perrigo guided to roughly 39% adjusted gross margin for calendar 2025 and reported third-quarter adjusted gross margin down 110 basis points to 39.9%, about 18 points below Kenvue. Haleon, the nearest pure-play, reported FY2025 gross margin up 350 basis points to 64.2% on revenue of £11.0 billion with 3.0% organic growth.

The honest overrated case: a brand moat that cannot grow units is a liquidation of goodwill at a controlled rate. Kenvue grew gross margin and shrank revenue in the same years Haleon grew organically, and the market share claims behind the Self Care defense are company statements with no third-party measure in the filings. Direction: narrowing.

What breaks it, and who

Private label is the live pressure. Store-brand internal analgesic liquids ran 40.5% of category sales on IRI data cited in industry press, store-brand acetaminophen and ibuprofen sit about 25% under national brands, and Perrigo flagged store-brand share gains inside a declining Americas self-care business. That is share moving at the exact point where Kenvue's premium is widest.

The second pressure is regulatory and it hits the asset directly. On September 22, 2025 the FDA initiated an acetaminophen label change citing possible association between prenatal use and autism and ADHD, over objections from ACOG and the American Pharmacists Association, and the FY2025 10-K lists acetaminophen and talc proceedings as risk factors.

The read changes on three items inside 12 to 18 months: the remaining foreign antitrust decisions and whether the Kimberly-Clark combination closes on its fourth-quarter 2026 target, whether Skin Health and Beauty revenue stops falling, and whether gross margin holds 58% without further volume loss.

Closing thoughts

The moat is real and narrowing. It is proven, by the margin numbers themselves, to be a price moat rather than a volume moat, and three consecutive years of declining skin and North America revenue against a faster-growing Haleon say the premium is being harvested rather than compounded. The checkable thing is segment revenue direction, specifically whether Skin Health and Beauty breaks its $4.38 billion to $4.11 billion slide, since consumption stabilization has so far been a company claim with no third-party measure in the filings reviewed. The moat strengthens if volume turns positive while gross margin holds near 58%, and weakens if gross margin is defended by further price with units still falling.